See the DrugPatentWatch profile for Kimmtrak
What is Kimmtrak (tebentafusp)?
Kimmtrak is a cancer medicine whose active ingredient is tebentafusp. It is used in certain cancers driven by a specific biomarker called HLA-A*02:01. [1]
For what cancer does Kimmtrak work?
Kimmtrak is prescribed for adults with unresectable or metastatic uveal melanoma who have the HLA-A*02:01 genotype. [1]
Who qualifies to take it?
Treatment depends on HLA-A*02:01 status; people who do not carry this genotype are not candidates based on the labeled indication described in the available source. [1]
How is Kimmtrak given (IV schedule)?
Kimmtrak is administered by infusion (intravenous). The first doses require careful monitoring due to infusion-related reactions; the prescribing information includes step-up dosing and observation requirements. [1]
What side effects do patients ask about most?
The most commonly discussed risks for tebentafusp include infusion-related reactions (such as fever, chills, and low blood pressure) and skin-related effects; the full range and severity are outlined in the prescribing information. [1]
Where does Kimmtrak fit vs other uveal melanoma options?
For unresectable or metastatic uveal melanoma with HLA-A*02:01, Kimmtrak is one systemic treatment option. Other therapies may be used depending on tumor characteristics, prior treatments, and clinical guidelines, but the HLA restriction is central to Kimmtrak’s use. [1]
What results does it claim?
The label describes clinically meaningful benefit in the studied population of adults with unresectable or metastatic uveal melanoma who are HLA-A*02:01 positive. [1]
How do patients find coverage or dosing access?
Coverage and logistics depend on the country, oncology clinic, and local formulary. Since Kimmtrak requires infusion administration and monitoring, many patients access it through specialty oncology centers following biomarker testing for HLA-A*02:01. [1]
---
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761118